University of Missouri Study Finds Resuming Blood Thinners Early After Flap Surgery Reduces Patient Complications

University of Missouri researchers find that restarting blood thinners 48 hours after flap surgery reduces complications and protects against vascular failure.

By: AXL Media

Published: Mar 10, 2026, 11:55 AM EDT

Source: The information in this article was sourced from University of Missouri-Columbia

Reevaluating Traditional Protocols for Perioperative Anticoagulation

The conventional medical practice of suspending blood thinners for extended periods before and after major surgery is facing new scrutiny following a study from the University of Missouri School of Medicine. Researchers tracking 470 patients who underwent complex free flap reconstructions discovered that the prolonged absence of these medications was actually associated with a higher rate of complications. This finding suggests that the fear of post-operative bleeding may be leading to overly cautious protocols that inadvertently increase the risk of vascular failure and clotting events.

The Delicate Balance of Clotting and Bleeding Risks

Free flap reconstruction is a sophisticated surgical technique used primarily in head and neck procedures, involving the transplantation of tissue from one part of the body to another. Because these operations rely on a robust and continuous blood supply to the newly moved tissue, any interruption in flow can be catastrophic. Lead author Megan Gillespie, MD, noted that the medical team must navigate two competing risks: excessive bleeding at the surgical site versus dangerous clotting that could lead to flap failure, heart attack, or stroke.

Identifying the Optimal Window for Resumption

Current data indicates that while the average wait time to resume blood thinners is roughly five days post-surgery, this duration may be unnecessarily long for most patients. Patrick Tassone, MD, an associate professor of otolaryngology and study co-author, suggested that resuming these medications after approximately 48 hours has proven effective in his personal clinical practice. This shorter window provides the "sweet spot" needed to protect the patient from systemic clotting issues without significantly increasing the likelihood of a secondary bleeding event that requires a return to the operating room.